16
Tue, Jul
71 New Articles

Life sciences in Romania, encompassing pharmaceuticals, biotechnology, and medical devices, is a sector marked by both significant challenges and promising opportunities. As the country continues to integrate into the European Union’s regulatory and economic frameworks and as those frameworks evolve and become more complex, Romania faces the constant task of aligning its local industry with European and international standards. This alignment is crucial for fostering innovation, ensuring public health, and attracting foreign investment. The industry’s growth is influenced by many factors, such as financing, pricing and reimbursement, regulatory compliance and product liability, and sustainable public procurement tools and processes.

Dorda, working with Linklaters, Kromann Reumert, and Wilson Sonsini Goodrich & Rosati, has advised Novo Holdings on its acquisition of Single Use Support. E+H advised the Single Use Support founders and Binder Groesswang advised Danaher on the sale side. Kirkland & Ellis reportedly advised Danaher as well.

In Serbia, most of the exclusivity arrangements between pharma companies need to be, prior to their implementation, individually exempt by the Serbian Competition Authority (“SCA”). Most recently, the SCA issued two decisions in the individual exemption process. In one it denied, while, in the other it only conditionally approved individual exemptions for exclusive distribution agreements between pharmaceutical companies. These developments show a noticeable shift in the SCA’s stand towards exclusivity arrangements with the SCA taking a stringent approach, limiting the parties' ability to contract exclusivity arrangements in the sector.

Filip & Company has advised the Centrokinetic orthopedics and medical rehabilitation network together with its shareholder, the Agista investment fund, on their acquisition of a 70% stake in the Socrates clinic in Timisoara, Romania. Timisoara-based sole practitioner Diana Pavel Cios reportedly advised the sellers.

More Articles ...

Our Latest Issue